| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 96 | 2024 | 7265 | 5.960 |
Why?
|
| Mutation | 73 | 2024 | 15912 | 3.030 |
Why?
|
| Myelodysplastic Syndromes | 33 | 2024 | 3156 | 2.760 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 29 | 2024 | 1013 | 1.990 |
Why?
|
| Isocitrate Dehydrogenase | 14 | 2024 | 522 | 1.960 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 12 | 2024 | 460 | 1.850 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 14 | 2024 | 838 | 1.690 |
Why?
|
| Neoplasms, Second Primary | 11 | 2024 | 1388 | 1.670 |
Why?
|
| Clonal Evolution | 9 | 2024 | 250 | 1.640 |
Why?
|
| Hematopoiesis | 9 | 2024 | 602 | 1.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2022 | 16689 | 1.330 |
Why?
|
| DNA Methylation | 9 | 2024 | 2765 | 1.240 |
Why?
|
| Antineoplastic Agents | 27 | 2024 | 14617 | 1.180 |
Why?
|
| Sulfonamides | 28 | 2024 | 1933 | 1.140 |
Why?
|
| Myeloproliferative Disorders | 8 | 2024 | 882 | 1.130 |
Why?
|
| Tumor Suppressor Protein p53 | 14 | 2024 | 3658 | 1.050 |
Why?
|
| Humans | 194 | 2024 | 270740 | 0.940 |
Why?
|
| Azacitidine | 13 | 2023 | 1218 | 0.920 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2024 | 5408 | 0.920 |
Why?
|
| Aged | 105 | 2024 | 73333 | 0.920 |
Why?
|
| Middle Aged | 102 | 2024 | 90352 | 0.850 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 5 | 2022 | 531 | 0.840 |
Why?
|
| Protein Kinase Inhibitors | 16 | 2022 | 4961 | 0.810 |
Why?
|
| Nuclear Proteins | 14 | 2024 | 3438 | 0.800 |
Why?
|
| Clone Cells | 3 | 2018 | 591 | 0.780 |
Why?
|
| Aged, 80 and over | 60 | 2024 | 30998 | 0.770 |
Why?
|
| Cytarabine | 14 | 2023 | 2014 | 0.760 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 126 | 0.740 |
Why?
|
| Thalidomide | 2 | 2022 | 597 | 0.730 |
Why?
|
| Neoplasm Proteins | 7 | 2024 | 3345 | 0.710 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 5 | 2024 | 214 | 0.710 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 10 | 2023 | 2635 | 0.700 |
Why?
|
| Male | 99 | 2024 | 128315 | 0.690 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2023 | 204 | 0.690 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1739 | 0.690 |
Why?
|
| Adult | 79 | 2024 | 82040 | 0.690 |
Why?
|
| Biomarkers, Tumor | 15 | 2022 | 10708 | 0.690 |
Why?
|
| Propensity Score | 6 | 2022 | 772 | 0.680 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2021 | 2486 | 0.670 |
Why?
|
| Idarubicin | 5 | 2022 | 459 | 0.660 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2022 | 2903 | 0.660 |
Why?
|
| Female | 101 | 2024 | 148940 | 0.660 |
Why?
|
| Prognosis | 40 | 2024 | 22505 | 0.650 |
Why?
|
| Hematologic Neoplasms | 6 | 2022 | 1956 | 0.650 |
Why?
|
| Protein Phosphatase 2C | 3 | 2024 | 86 | 0.620 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2024 | 2617 | 0.620 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 49 | 0.610 |
Why?
|
| Dioxygenases | 4 | 2024 | 173 | 0.600 |
Why?
|
| Germ Cells | 2 | 2020 | 329 | 0.590 |
Why?
|
| Fluoroquinolones | 4 | 2020 | 135 | 0.590 |
Why?
|
| Molecular Targeted Therapy | 4 | 2024 | 2399 | 0.590 |
Why?
|
| Recurrence | 12 | 2024 | 4878 | 0.590 |
Why?
|
| Dasatinib | 8 | 2022 | 881 | 0.580 |
Why?
|
| High-Throughput Nucleotide Sequencing | 15 | 2023 | 2359 | 0.580 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2022 | 586 | 0.570 |
Why?
|
| Bone Marrow | 14 | 2023 | 2441 | 0.570 |
Why?
|
| Remission Induction | 16 | 2022 | 3656 | 0.570 |
Why?
|
| Survival Rate | 24 | 2023 | 12541 | 0.560 |
Why?
|
| Neoplasms | 12 | 2024 | 15927 | 0.540 |
Why?
|
| Precision Medicine | 1 | 2024 | 1207 | 0.540 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2015 | 26 | 0.510 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 68 | 0.510 |
Why?
|
| Repressor Proteins | 6 | 2024 | 1718 | 0.510 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 65 | 0.510 |
Why?
|
| ras Proteins | 3 | 2022 | 804 | 0.500 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2020 | 2453 | 0.490 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2024 | 1367 | 0.490 |
Why?
|
| Young Adult | 33 | 2024 | 22251 | 0.490 |
Why?
|
| GTP Phosphohydrolases | 2 | 2016 | 339 | 0.480 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 1942 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 10400 | 0.470 |
Why?
|
| Stem Cells | 1 | 2021 | 1216 | 0.470 |
Why?
|
| Follow-Up Studies | 25 | 2021 | 15218 | 0.460 |
Why?
|
| Genomics | 5 | 2020 | 2835 | 0.460 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 469 | 0.450 |
Why?
|
| Philadelphia Chromosome | 7 | 2022 | 852 | 0.440 |
Why?
|
| Primary Myelofibrosis | 4 | 2018 | 914 | 0.430 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 1557 | 0.430 |
Why?
|
| Chromosome Deletion | 3 | 2021 | 1049 | 0.430 |
Why?
|
| Sequence Analysis, DNA | 7 | 2023 | 2573 | 0.430 |
Why?
|
| Germ-Line Mutation | 6 | 2020 | 1101 | 0.430 |
Why?
|
| Single-Cell Analysis | 4 | 2021 | 557 | 0.420 |
Why?
|
| Aminopyridines | 4 | 2022 | 223 | 0.420 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 331 | 0.420 |
Why?
|
| Oxazines | 1 | 2012 | 41 | 0.420 |
Why?
|
| Pyelonephritis | 1 | 2012 | 46 | 0.420 |
Why?
|
| Mutant Proteins | 1 | 2013 | 234 | 0.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2024 | 7044 | 0.410 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2016 | 441 | 0.410 |
Why?
|
| Triazines | 3 | 2022 | 121 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2024 | 1542 | 0.400 |
Why?
|
| Glycine | 3 | 2024 | 322 | 0.390 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 993 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 275 | 0.390 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 968 | 0.380 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 9039 | 0.370 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 513 | 0.370 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2023 | 460 | 0.370 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1402 | 0.370 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 402 | 0.360 |
Why?
|
| Cell Nucleus | 1 | 2016 | 1712 | 0.350 |
Why?
|
| Treatment Outcome | 32 | 2024 | 33737 | 0.350 |
Why?
|
| Janus Kinase 2 | 2 | 2019 | 754 | 0.350 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2019 | 1144 | 0.340 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1340 | 0.340 |
Why?
|
| DNA-Binding Proteins | 6 | 2024 | 5002 | 0.340 |
Why?
|
| Retrospective Studies | 31 | 2024 | 39890 | 0.330 |
Why?
|
| Transcription Factors | 6 | 2024 | 5438 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 3187 | 0.310 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 670 | 0.310 |
Why?
|
| Pyridines | 4 | 2024 | 1313 | 0.310 |
Why?
|
| Cohort Studies | 9 | 2024 | 9470 | 0.310 |
Why?
|
| Urinary Tract Infections | 4 | 2020 | 345 | 0.300 |
Why?
|
| Epigenesis, Genetic | 5 | 2023 | 1441 | 0.300 |
Why?
|
| Benzimidazoles | 3 | 2022 | 437 | 0.290 |
Why?
|
| Disease-Free Survival | 14 | 2020 | 10265 | 0.290 |
Why?
|
| Drug Administration Schedule | 10 | 2020 | 3530 | 0.280 |
Why?
|
| Survival Analysis | 12 | 2020 | 9292 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2021 | 6256 | 0.270 |
Why?
|
| Membrane Proteins | 2 | 2016 | 2928 | 0.270 |
Why?
|
| Gene Frequency | 5 | 2021 | 1246 | 0.270 |
Why?
|
| Translocation, Genetic | 4 | 2023 | 1286 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2021 | 234 | 0.260 |
Why?
|
| Radiotherapy | 1 | 2013 | 1857 | 0.260 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4795 | 0.260 |
Why?
|
| Adolescent | 24 | 2024 | 32767 | 0.260 |
Why?
|
| Vidarabine | 6 | 2022 | 1384 | 0.260 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 1137 | 0.260 |
Why?
|
| Genes, p53 | 2 | 2022 | 1140 | 0.260 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2023 | 314 | 0.250 |
Why?
|
| Phenotype | 4 | 2024 | 6509 | 0.250 |
Why?
|
| Artificial Intelligence | 2 | 2020 | 425 | 0.240 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2018 | 232 | 0.240 |
Why?
|
| DNA Helicases | 2 | 2024 | 450 | 0.240 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2024 | 36 | 0.240 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2024 | 131 | 0.230 |
Why?
|
| Models, Biological | 4 | 2022 | 3194 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2020 | 430 | 0.230 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 896 | 0.230 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 2115 | 0.220 |
Why?
|
| Blood Platelet Disorders | 1 | 2024 | 35 | 0.220 |
Why?
|
| Imatinib Mesylate | 3 | 2019 | 1691 | 0.220 |
Why?
|
| Chromosome Inversion | 2 | 2023 | 197 | 0.220 |
Why?
|
| Doxorubicin | 6 | 2021 | 3145 | 0.220 |
Why?
|
| Histone Demethylases | 2 | 2023 | 144 | 0.220 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2021 | 121 | 0.210 |
Why?
|
| Dexamethasone | 7 | 2022 | 1516 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 3409 | 0.210 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 288 | 0.210 |
Why?
|
| Antigens, CD19 | 2 | 2023 | 584 | 0.210 |
Why?
|
| Adenine | 4 | 2021 | 674 | 0.210 |
Why?
|
| Piperidines | 5 | 2021 | 1100 | 0.210 |
Why?
|
| Leukemia | 3 | 2024 | 1719 | 0.210 |
Why?
|
| Pyrimidines | 5 | 2019 | 3669 | 0.210 |
Why?
|
| Daunorubicin | 2 | 2020 | 314 | 0.200 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2022 | 6 | 0.200 |
Why?
|
| Triazoles | 2 | 2024 | 627 | 0.200 |
Why?
|
| Gene Rearrangement | 2 | 2023 | 813 | 0.200 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2022 | 71 | 0.200 |
Why?
|
| Salvage Therapy | 5 | 2021 | 2123 | 0.200 |
Why?
|
| Acute Disease | 6 | 2024 | 2493 | 0.200 |
Why?
|
| Alleles | 3 | 2019 | 2600 | 0.200 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 14849 | 0.190 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2021 | 14 | 0.190 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 870 | 0.190 |
Why?
|
| Signal Transduction | 7 | 2024 | 12103 | 0.190 |
Why?
|
| WT1 Proteins | 1 | 2022 | 107 | 0.190 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2021 | 48 | 0.180 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 115 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2020 | 1076 | 0.180 |
Why?
|
| Enterococcus faecalis | 3 | 2020 | 60 | 0.180 |
Why?
|
| Mice | 15 | 2024 | 35600 | 0.180 |
Why?
|
| Exanthema | 2 | 2020 | 212 | 0.180 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 172 | 0.180 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2021 | 84 | 0.180 |
Why?
|
| Pyrazoles | 3 | 2019 | 1546 | 0.180 |
Why?
|
| Antibodies, Bispecific | 2 | 2022 | 282 | 0.180 |
Why?
|
| Animals | 19 | 2024 | 61956 | 0.180 |
Why?
|
| Neoplasm, Residual | 6 | 2022 | 1754 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 244 | 0.180 |
Why?
|
| Tandem Repeat Sequences | 3 | 2020 | 203 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 1347 | 0.180 |
Why?
|
| Genes, ras | 3 | 2022 | 679 | 0.170 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 223 | 0.170 |
Why?
|
| HIV Infections | 1 | 2012 | 2154 | 0.170 |
Why?
|
| Core Binding Factors | 2 | 2022 | 112 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2020 | 108 | 0.170 |
Why?
|
| Neoplasm Staging | 6 | 2016 | 14012 | 0.170 |
Why?
|
| Megakaryocyte-Erythroid Progenitor Cells | 1 | 2019 | 5 | 0.170 |
Why?
|
| Epigenomics | 1 | 2021 | 273 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 5776 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2023 | 2313 | 0.170 |
Why?
|
| Multigene Family | 1 | 2021 | 469 | 0.170 |
Why?
|
| Risk Factors | 8 | 2024 | 17888 | 0.170 |
Why?
|
| Siblings | 1 | 2021 | 319 | 0.170 |
Why?
|
| Karyotype | 4 | 2022 | 237 | 0.160 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2020 | 115 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 324 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 690 | 0.160 |
Why?
|
| Biological Products | 1 | 2022 | 319 | 0.160 |
Why?
|
| Microfluidics | 1 | 2018 | 32 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2020 | 287 | 0.160 |
Why?
|
| Heterografts | 1 | 2020 | 738 | 0.150 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 520 | 0.150 |
Why?
|
| Drug Evaluation | 2 | 2020 | 432 | 0.150 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 2328 | 0.150 |
Why?
|
| Retreatment | 2 | 2016 | 448 | 0.150 |
Why?
|
| Cyclophosphamide | 6 | 2021 | 3245 | 0.150 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 120 | 0.150 |
Why?
|
| Age Factors | 7 | 2020 | 5457 | 0.150 |
Why?
|
| Anemia | 1 | 2024 | 728 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4831 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 232 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2019 | 166 | 0.150 |
Why?
|
| Mycoses | 1 | 2021 | 393 | 0.150 |
Why?
|
| Rituximab | 2 | 2021 | 1594 | 0.150 |
Why?
|
| Prospective Studies | 9 | 2024 | 13414 | 0.140 |
Why?
|
| Arabinonucleosides | 2 | 2021 | 470 | 0.140 |
Why?
|
| Time Factors | 7 | 2019 | 13006 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 840 | 0.140 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 867 | 0.140 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2016 | 19 | 0.140 |
Why?
|
| Chlamydia trachomatis | 1 | 2016 | 30 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2020 | 291 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 1568 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 929 | 0.130 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 49 | 0.130 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 123 | 0.130 |
Why?
|
| Models, Genetic | 1 | 2020 | 1163 | 0.130 |
Why?
|
| PC12 Cells | 1 | 2016 | 54 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 205 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2020 | 510 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 1099 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1840 | 0.130 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2015 | 23 | 0.130 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2015 | 43 | 0.130 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 99 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2019 | 3045 | 0.130 |
Why?
|
| Escherichia coli | 4 | 2020 | 1305 | 0.130 |
Why?
|
| Computational Biology | 1 | 2021 | 1291 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2022 | 533 | 0.120 |
Why?
|
| Bacteria | 1 | 2020 | 654 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2019 | 672 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 274 | 0.120 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 254 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2016 | 162 | 0.120 |
Why?
|
| Vincristine | 4 | 2021 | 1583 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2015 | 78 | 0.120 |
Why?
|
| Mesoderm | 1 | 2017 | 392 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1097 | 0.120 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 92 | 0.120 |
Why?
|
| Gram-Negative Bacteria | 1 | 2015 | 107 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2022 | 770 | 0.120 |
Why?
|
| RNA Splicing Factors | 1 | 2015 | 151 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2021 | 1418 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 295 | 0.120 |
Why?
|
| Antifungal Agents | 4 | 2024 | 880 | 0.120 |
Why?
|
| Apoptosis | 3 | 2024 | 7757 | 0.120 |
Why?
|
| Mitochondria | 1 | 2021 | 1297 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2015 | 365 | 0.110 |
Why?
|
| Patients | 1 | 2016 | 246 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2016 | 822 | 0.110 |
Why?
|
| Gene Expression | 3 | 2016 | 3640 | 0.110 |
Why?
|
| Transplantation Conditioning | 2 | 2021 | 2374 | 0.110 |
Why?
|
| Protein Transport | 1 | 2016 | 737 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1034 | 0.110 |
Why?
|
| Chromosome Aberrations | 3 | 2018 | 2035 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2019 | 1608 | 0.110 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2018 | 5694 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2016 | 2090 | 0.110 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 2810 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2016 | 668 | 0.110 |
Why?
|
| Japan | 3 | 2020 | 241 | 0.100 |
Why?
|
| Exome | 2 | 2015 | 1248 | 0.100 |
Why?
|
| Nucleosomes | 1 | 2013 | 152 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1958 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 3949 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 1525 | 0.100 |
Why?
|
| Transcriptome | 4 | 2023 | 1963 | 0.100 |
Why?
|
| Family | 1 | 2016 | 783 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1903 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2015 | 647 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 657 | 0.100 |
Why?
|
| Thrombocythemia, Essential | 1 | 2013 | 179 | 0.100 |
Why?
|
| RNA Interference | 1 | 2016 | 1388 | 0.100 |
Why?
|
| Levofloxacin | 2 | 2020 | 57 | 0.090 |
Why?
|
| Cisplatin | 1 | 2018 | 2497 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2375 | 0.090 |
Why?
|
| Virulence Factors | 1 | 2012 | 233 | 0.090 |
Why?
|
| Gene Duplication | 1 | 2013 | 442 | 0.090 |
Why?
|
| Disease Progression | 5 | 2024 | 6867 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 256 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2224 | 0.090 |
Why?
|
| Polycythemia Vera | 1 | 2013 | 268 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2057 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 1093 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 512 | 0.090 |
Why?
|
| Incidence | 2 | 2019 | 5824 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2015 | 797 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 272 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2016 | 6224 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1138 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1125 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2018 | 1465 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 5056 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2018 | 1696 | 0.080 |
Why?
|
| Receptor, Notch1 | 2 | 2022 | 217 | 0.080 |
Why?
|
| Entropy | 1 | 2009 | 36 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2013 | 825 | 0.080 |
Why?
|
| Sex Factors | 4 | 2020 | 2184 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 5101 | 0.080 |
Why?
|
| Heparin | 1 | 2011 | 342 | 0.080 |
Why?
|
| Cladribine | 2 | 2022 | 253 | 0.080 |
Why?
|
| Aging | 2 | 2009 | 1534 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 12033 | 0.080 |
Why?
|
| Texas | 2 | 2016 | 6449 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2020 | 252 | 0.080 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 574 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4895 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2019 | 7238 | 0.080 |
Why?
|
| Proteus mirabilis | 2 | 2020 | 16 | 0.080 |
Why?
|
| Rats | 2 | 2016 | 6441 | 0.080 |
Why?
|
| Comorbidity | 3 | 2024 | 2394 | 0.080 |
Why?
|
| Visual Perception | 1 | 2009 | 149 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2024 | 4116 | 0.080 |
Why?
|
| Spleen | 2 | 2024 | 726 | 0.070 |
Why?
|
| Photic Stimulation | 1 | 2009 | 272 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2016 | 4942 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2098 | 0.070 |
Why?
|
| Klebsiella pneumoniae | 2 | 2020 | 101 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2022 | 575 | 0.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2010 | 372 | 0.070 |
Why?
|
| Proteolysis | 2 | 2020 | 380 | 0.070 |
Why?
|
| Graft Survival | 1 | 2010 | 1083 | 0.070 |
Why?
|
| Imidazoles | 2 | 2022 | 1065 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2018 | 2353 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 4328 | 0.060 |
Why?
|
| DNA Repair | 2 | 2024 | 1909 | 0.060 |
Why?
|
| Vancomycin | 2 | 2020 | 292 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2011 | 775 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2018 | 6764 | 0.060 |
Why?
|
| DNA Damage | 2 | 2024 | 1989 | 0.060 |
Why?
|
| Genome, Human | 1 | 2013 | 1888 | 0.060 |
Why?
|
| Fractals | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2009 | 623 | 0.060 |
Why?
|
| Nitriles | 2 | 2021 | 939 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1655 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 2 | 2024 | 1456 | 0.060 |
Why?
|
| Neutropenia | 2 | 2019 | 1006 | 0.060 |
Why?
|
| Karyotyping | 2 | 2017 | 1063 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3077 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 1939 | 0.060 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2024 | 32 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3917 | 0.060 |
Why?
|
| Erythroid Cells | 1 | 2024 | 53 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2009 | 991 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.060 |
Why?
|
| Voriconazole | 1 | 2024 | 115 | 0.050 |
Why?
|
| Arachidonic Acid | 1 | 2023 | 120 | 0.050 |
Why?
|
| Pedigree | 2 | 2019 | 2042 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 6177 | 0.050 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2002 | 12 | 0.050 |
Why?
|
| Citrus | 1 | 2002 | 8 | 0.050 |
Why?
|
| Ofloxacin | 1 | 2002 | 43 | 0.050 |
Why?
|
| Lactams | 1 | 2002 | 27 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4372 | 0.050 |
Why?
|
| Income | 1 | 2023 | 235 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 162 | 0.050 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2002 | 53 | 0.050 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2022 | 37 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2024 | 338 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2024 | 572 | 0.050 |
Why?
|
| Regenerative Medicine | 1 | 2022 | 39 | 0.050 |
Why?
|
| Beverages | 1 | 2002 | 104 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5574 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2002 | 101 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 67 | 0.050 |
Why?
|
| Tumor Hypoxia | 1 | 2022 | 25 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 2357 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2002 | 201 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2022 | 233 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 94 | 0.050 |
Why?
|
| Splicing Factor U2AF | 1 | 2021 | 47 | 0.050 |
Why?
|
| Capsid | 1 | 2002 | 178 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 322 | 0.050 |
Why?
|
| NAD | 1 | 2021 | 87 | 0.050 |
Why?
|
| Algorithms | 2 | 2023 | 3891 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2023 | 427 | 0.050 |
Why?
|
| Azoles | 1 | 2021 | 48 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2002 | 219 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2024 | 588 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2022 | 147 | 0.050 |
Why?
|
| Mercaptopurine | 1 | 2021 | 130 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 60 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2020 | 17061 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2020 | 41 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 362 | 0.050 |
Why?
|
| PPAR gamma | 1 | 2022 | 225 | 0.050 |
Why?
|
| Phylogeny | 1 | 2023 | 867 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2021 | 318 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 1199 | 0.040 |
Why?
|
| Iron | 1 | 2024 | 380 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2020 | 40 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 153 | 0.040 |
Why?
|
| Doxycycline | 1 | 2021 | 179 | 0.040 |
Why?
|
| Asparaginase | 1 | 2021 | 196 | 0.040 |
Why?
|
| Glutamine | 1 | 2022 | 324 | 0.040 |
Why?
|
| Body Surface Area | 1 | 2020 | 42 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 9042 | 0.040 |
Why?
|
| Child | 5 | 2020 | 30559 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2020 | 198 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 7100 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2002 | 450 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2002 | 382 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 271 | 0.040 |
Why?
|
| Prodrugs | 1 | 2021 | 226 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2024 | 677 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 1005 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5257 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2023 | 1179 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8699 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2023 | 3557 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 686 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2021 | 648 | 0.040 |
Why?
|
| Colon | 1 | 2002 | 659 | 0.040 |
Why?
|
| Pyridazines | 1 | 2022 | 324 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 593 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2022 | 1356 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 2650 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 827 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 3597 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 74 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 1034 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 3046 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 701 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 485 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2021 | 5728 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 661 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2024 | 1149 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 164 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 1322 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 178 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1060 | 0.040 |
Why?
|
| Methotrexate | 1 | 2021 | 1025 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 198 | 0.040 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 2017 | 19 | 0.040 |
Why?
|
| Luciferases | 2 | 2013 | 460 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 16215 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2024 | 1563 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 5051 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 1826 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 460 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2315 | 0.030 |
Why?
|
| Urethritis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 561 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2017 | 143 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2017 | 107 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2021 | 821 | 0.030 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2016 | 25 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 64 | 0.030 |
Why?
|
| Infant | 3 | 2020 | 13999 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2002 | 1497 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 1584 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1726 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 925 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 341 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2019 | 372 | 0.030 |
Why?
|
| beta Catenin | 1 | 2020 | 683 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1076 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 1002 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2021 | 1418 | 0.030 |
Why?
|
| Klebsiella oxytoca | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2019 | 505 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1090 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2021 | 1184 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 502 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2022 | 1110 | 0.030 |
Why?
|
| Serratia marcescens | 1 | 2015 | 21 | 0.030 |
Why?
|
| Imipenem | 1 | 2015 | 28 | 0.030 |
Why?
|
| Amikacin | 1 | 2015 | 37 | 0.030 |
Why?
|
| Linezolid | 1 | 2015 | 71 | 0.030 |
Why?
|
| Ampicillin | 1 | 2015 | 68 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 203 | 0.030 |
Why?
|
| Itraconazole | 1 | 2015 | 82 | 0.030 |
Why?
|
| Codon | 1 | 2015 | 261 | 0.030 |
Why?
|
| Genes, myc | 1 | 2017 | 371 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2015 | 183 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 784 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 680 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 533 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2015 | 91 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 245 | 0.030 |
Why?
|
| Mosaicism | 1 | 2017 | 293 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 279 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6390 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2015 | 298 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1461 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 264 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 257 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 1580 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2015 | 298 | 0.030 |
Why?
|
| Cell Movement | 1 | 2022 | 2472 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 655 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 531 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2018 | 727 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 848 | 0.030 |
Why?
|
| DNA | 1 | 2002 | 3050 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 608 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2016 | 417 | 0.030 |
Why?
|
| Interphase | 1 | 2013 | 156 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2015 | 214 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 5759 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2019 | 1624 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2013 | 220 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 885 | 0.030 |
Why?
|
| Chromosomes | 1 | 2013 | 325 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 1275 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 1059 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 730 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 507 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1192 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2013 | 186 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 2828 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 850 | 0.020 |
Why?
|
| New York City | 1 | 2011 | 75 | 0.020 |
Why?
|
| Brain | 1 | 2004 | 4208 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2017 | 1389 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 276 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 2025 | 0.020 |
Why?
|
| Mitosis | 1 | 2013 | 681 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3035 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3484 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 931 | 0.020 |
Why?
|
| Platelet Count | 1 | 2011 | 492 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 706 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 3444 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2010 | 323 | 0.020 |
Why?
|
| Evoked Potentials, Visual | 1 | 2009 | 39 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4481 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2027 | 0.020 |
Why?
|
| Sensation | 1 | 2009 | 73 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 1838 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 3844 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 202 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2010 | 388 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2013 | 1570 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 3117 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 1757 | 0.020 |
Why?
|
| Melphalan | 1 | 2010 | 879 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3063 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 3584 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7655 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4960 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2009 | 326 | 0.020 |
Why?
|
| Busulfan | 1 | 2010 | 794 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 1828 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 3086 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2005 | 243 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2004 | 57 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5149 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 452 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2011 | 917 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2005 | 383 | 0.010 |
Why?
|
| beta-Lactams | 1 | 2002 | 63 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2002 | 239 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 4019 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 2167 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 2002 | 153 | 0.010 |
Why?
|
| Carcinogens | 1 | 2002 | 390 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2004 | 624 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2004 | 1145 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 520 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 2220 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 804 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1690 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 1857 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2002 | 1716 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 7895 | 0.000 |
Why?
|